Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Johnson and Johnson
AstraZeneca
McKesson
Moodys

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Us Pharm Holdings Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for US PHARM HOLDINGS, and what generic and branded alternatives to US PHARM HOLDINGS drugs are available?

US PHARM HOLDINGS has ten approved drugs.



Summary for Us Pharm Holdings
US Patents:0
Tradenames:10
Ingredients:8
NDAs:10

Drugs and US Patents for Us Pharm Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 DISCN Yes No   Start Trial   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-005 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial
Us Pharm Holdings TRENTAL pentoxifylline TABLET, EXTENDED RELEASE;ORAL 018631-001 Aug 30, 1984 DISCN Yes No   Start Trial   Start Trial
Us Pharm Holdings LASIX furosemide TABLET;ORAL 016273-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial
Us Pharm Holdings ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 DISCN Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Us Pharm Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings TRENTAL pentoxifylline TABLET, EXTENDED RELEASE;ORAL 018631-001 Aug 30, 1984 3,737,433   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-007 Feb 11, 1982 3,454,554   Start Trial
Us Pharm Holdings NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 3,454,554   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
McKinsey
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.